Base de dados : MEDLINE
Pesquisa : C07.465.075 [Categoria DeCS]
Referências encontradas : 8113 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 812 ir para página                         

  1 / 8113 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468639
[Au] Autor:Sasajima H; Yagi S; Osada H; Zako M
[Ad] Endereço:Department of Ophthalmology, Aichi Medical University, Nagakute, Aichi, Japan.
[Ti] Título:Botulinum toxin-induced acute anterior uveitis in a patient with Behçet's disease under infliximab treatment: a case report.
[So] Source:J Med Case Rep;11(1):124, 2017 May 04.
[Is] ISSN:1752-1947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Injections of lipopolysaccharide in animal models generate acute anterior uveitis (also known as endotoxin-induced uveitis), but the effects of lipopolysaccharide injection are unknown in humans. We describe an unusual case in which acute anterior uveitis was dramatically activated subsequent to botulinum toxin injection in a patient with Behçet's disease but the acute anterior uveitis was satisfactorily attenuated by infliximab. CASE PRESENTATION: A 53-year-old Japanese man had normal ocular findings at his regularly scheduled appointment. He had been diagnosed as having incomplete-type Behçet's disease 11 years before. Three years after the diagnosis he was given systemic infusions of 5 mg/kg infliximab every 8 weeks and he had not experienced a uveitis attack for 8 years with no treatment other than infliximab. Two days after the eye examination, he received intracutaneous botulinum toxin injections to treat axillary hyperhidrosis on both sides. Three hours after the injections, he noted rapidly increasing floaters in his right eye. Four days after the injections, his right eye showed severe acute anterior uveitis with deteriorated aqueous flare and anterior vitreous opacity. He received his scheduled infliximab injection, and the right acute anterior uveitis immediately attenuated. CONCLUSIONS: Botulinum toxin may have clinical effects similar to those of lipopolysaccharide in endotoxin-induced uveitis models. To the best of our knowledge, this is the first report to suggest that botulinum toxin may trigger acute anterior uveitis, although the precise mechanism is still unclear.
[Mh] Termos MeSH primário: Síndrome de Behçet/tratamento farmacológico
Toxinas Botulínicas/efeitos adversos
Hiperidrose/tratamento farmacológico
Infliximab/administração & dosagem
Neurotoxinas/administração & dosagem
Uveíte/induzido quimicamente
[Mh] Termos MeSH secundário: Seres Humanos
Injeções Subcutâneas
Masculino
Meia-Idade
Tomografia de Coerência Óptica
Uveíte/diagnóstico por imagem
Uveíte/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neurotoxins); B72HH48FLU (Infliximab); EC 3.4.24.69 (Botulinum Toxins)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1288-1


  2 / 8113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390339
[Au] Autor:Chen Y; Shen Y; Ma HF; Cai JF; Hua YQ; Zou J; Guan JL
[Ad] Endereço:Rheumatology and Immunology Department.
[Ti] Título:Infliximab associated with life-threatening lung infection in a patient with Behcet disease with intestinal and hematopoietic system involvement: A case report.
[So] Source:Medicine (Baltimore);96(50):e9202, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Tumor necrosis factor (TNF-α) participates in the pathophysiology of Behcet's disease (BD) and myelodysplastic syndrome (MDS). Infliximab is recommaned for the most severe type of BD, however, there is little evidence for its effectiveness in BD associated MDS. PATIENT CONCERNS: A 46-year-old female, initially diagnosed with intestinal BD and leukopenia was later diagnosed as MDS. Treatement with infliximab and other immunoregulators lead to life-threatening pneumonia. DIAGNOSIS: Intestinal BD associated with MDS involving trisomy 8. INTERVENTIONS: The patient initially treated with methylprednisolone, thalidomide, cyclosporine A, and infliximab, which lead to severe lung infection. Therefore, the patient was transferred to Intensive Care Unit for life supportive, anti-infection and immune improving therapy. OUTCOMES: The patient survived from the lung infection. With combination of methylprednisolone, thalidomide and cyclosporine A, the patient recovered from her intestinal ulceration and MDS manifestations. LESSONS: Infliximab treatment may not benefit a patient with BD associated with MDS but place the patient at risk of infection.
[Mh] Termos MeSH primário: Antirreumáticos/efeitos adversos
Antirreumáticos/uso terapêutico
Síndrome de Behçet/complicações
Síndrome de Behçet/tratamento farmacológico
Infliximab/efeitos adversos
Infliximab/uso terapêutico
Síndromes Mielodisplásicas/tratamento farmacológico
Síndromes Mielodisplásicas/etiologia
Pneumonia/induzido quimicamente
[Mh] Termos MeSH secundário: Ciclosporina/uso terapêutico
Feminino
Glucocorticoides/uso terapêutico
Seres Humanos
Imunossupressores/uso terapêutico
Metilprednisolona/uso terapêutico
Meia-Idade
Talidomida/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antirheumatic Agents); 0 (Glucocorticoids); 0 (Immunosuppressive Agents); 4Z8R6ORS6L (Thalidomide); 83HN0GTJ6D (Cyclosporine); B72HH48FLU (Infliximab); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009202


  3 / 8113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29269695
[Au] Autor:Hamada K; Takei R; Sakiyama Y; Moriyama H; Hashiguchi A; Takashima H
[Ad] Endereço:Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences.
[Ti] Título:[A case of chronic progressive neuro-Behçet disease with extensive cerebral atrophy and elevated CSF IL-6 activity treated with infliximab].
[So] Source:Rinsho Shinkeigaku;58(1):30-34, 2018 Jan 26.
[Is] ISSN:1882-0654
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:A 43-year-old man without a previous episode of uveitis presented with slowly progressive neurological symptoms that appeared within the past year such as dysarthria, ataxic gait, and behavioral changes. Brain MRI findings showed atrophic lesions in the brainstem and cerebellum. Because these clinical symptoms and abnormal MRI findings indicated spinocerebellar degeneration as the initial diagnosis, he was admitted to our hospital. On admission, we noticed that he had non-neurological manifestations of Behçet disease, such as stomatitis, genital ulcers, and folliculitis. HLA-B51 was positive. He also showed pleocytosis (29 cells/mm , predominantly mononuclear cells) and elevated cerebrospinal fluid (CSF) IL-6 levels (213 pg/ml), hence he was diagnosed with chronic progressive neuro-Behçet disease (CPNBD). The therapeutic effect of a high-dose intravenous methylprednisolone pulse (1,000 mg/day for 3 days) and methotrexate (maximum dosage, 16 mg/week) was poor against both neurological symptoms and CSF findings. Intravenous infliximab therapy (5 mg/kg, 2 weeks) dramatically decreased CSF IL-6 levels (13 pg/ml) but clinical symptoms remained unchanged. MRI findings of extensive cerebral atrophy and increased CSF IL-6 levels at the pretreatment time point reflected irreversible neurological involvement in CPNBD. For cases with progressive psychiatric symptoms and cerebellar ataxia in the early stage of the disease, skin manifestations should be examined immediately, CSF IL-6 levels measured, and immunosuppressive therapy initiated before CPNBD progresses to brainstem atrophy.
[Mh] Termos MeSH primário: Síndrome de Behçet/diagnóstico
Síndrome de Behçet/tratamento farmacológico
Encéfalo/patologia
Infliximab/administração & dosagem
Interleucina-6/líquido cefalorraquidiano
[Mh] Termos MeSH secundário: Adulto
Atrofia
Síndrome de Behçet/líquido cefalorraquidiano
Síndrome de Behçet/patologia
Biomarcadores/líquido cefalorraquidiano
Doença Crônica
Progressão da Doença
Seres Humanos
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Interleukin-6); B72HH48FLU (Infliximab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE
[do] DOI:10.5692/clinicalneurol.cn-001086


  4 / 8113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443756
[Au] Autor:Zhu Z; Shu X; Long S; Jiang X; Lu N; Zhu X; Liao W
[Ad] Endereço:Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
[Ti] Título:Ulcerative colitis followed by the development of typical intestinal Behçet disease: A case report.
[So] Source:Medicine (Baltimore);97(7):e9882, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Intestinal Behçet disease (intestinal BD) and inflammatory bowel disease (IBD) share a lot of characteristics, including genetic background, clinical manifestations, and therapeutic strategies, especially the extraintestinal manifestations, such as oral ulcers, arthralgia, eye lesions, skin lesions, etc, but the coexistence of these 2 diseases are uncommon. Behçet disease with gastrointestinal involvement in ulcerative colitis (UC) patient has been reported in just 1 previous case report, but, which can not be diagnosed as definite intestinal BD based on Korean novel diagnositic criteria due to lacking the typical ileocecal ulcer. PATIENT CONCERNS: We present a 23-year-old woman with ulcerative disease who developed typical intestinal BD, which is the first case report of patient with coexisting UC and typical intestinal BD. DIAGNOSES: This patient was diagnosed as coexistence of intestinal BD and UC base on the clinical manifestations, extra intestinal manifestations and typical colonoscopic findings. INTERVENTIONS: Steroid and methotrexate were administered. OUTCOMES: This patient achieved clinical remission and mucosal healing. LESSONS: Coexistence of intestinal BD and UC is uncommon, and the combination with steroid, methotrexate, and 5-aminosalicylic acids is an effective therapy.
[Mh] Termos MeSH primário: Síndrome de Behçet
Colite Ulcerativa
Colonoscopia/métodos
Trato Gastrointestinal
Glucocorticoides/administração & dosagem
Mesalamina/administração & dosagem
Metotrexato/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Anti-Inflamatórios não Esteroides/administração & dosagem
Antirreumáticos/administração & dosagem
Síndrome de Behçet/complicações
Síndrome de Behçet/diagnóstico
Síndrome de Behçet/fisiopatologia
Colite Ulcerativa/complicações
Colite Ulcerativa/diagnóstico
Colite Ulcerativa/fisiopatologia
Trato Gastrointestinal/diagnóstico por imagem
Trato Gastrointestinal/patologia
Seres Humanos
Masculino
Indução de Remissão
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Antirheumatic Agents); 0 (Glucocorticoids); 4Q81I59GXC (Mesalamine); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009882


  5 / 8113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29429506
[Au] Autor:Jachiet M; Rybojad M; Bouaziz JD
[Ad] Endereço:Service de dermatologie, hôpital Saint-Louis, INSERM U976, université Paris-Diderot-Paris VII, Sorbonne-Paris-Cité, Paris, France.
[Ti] Título:[What's new in internal medecine?]
[Ti] Título:Quoi de neuf en médecine interne ?.
[So] Source:Ann Dermatol Venereol;143 Suppl 3:S23-S28, 2016 Dec.
[Is] ISSN:0151-9638
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Answering the question « what's new in internal medecine in 2016? ¼ is very challenging. We used 3 methods of article selection to reduce the selection bias: 3 authors, a systematic review of the articles discussed in the weekly bibliographic meeting of our unit (Dermatology department, Saint-Louis Hospital, Paris, France) and a selection of the best articles by several internal medecine practitioners in Paris. Eleven « hot topics ¼ were analyzed: i/lowering cholesterol level but not blood blessure has a significant impact on cardiovascular morbi-mortality in cardiovascular intermediate risk patients; ii/the « treat to treat target ¼ is efficient in psoriatic arthritis; iii/ a genotype/ phenotype correlation favors the separation of ileal Crohn's disease, colonic Crohn's disease and ulcerative colitis; iv/ tocilizumab treatment (anti-IL-6 monoclonal antibody ) is very efficient in giant cell arteritis and slightly efficient in systemic sclerosis; v/ combination therapy using methotrexate plus steroids compared with steroids alone becomes the « gold standard ¼ treatment for juvenile dermatomyositis; vi/ dupilumab treatment (antibody blocking IL-4 and IL-13 receptors) is not only efficient in atopic dermatitis but also in asthma; vii/ think of eosinophilic oesophagitis in a patient with atopic dermatitis and dypshagia or food impaction; viii/ genetic A2 protein dysfunction induces NF-kB hyperactivation and an autoinflammatory disorder with features similar to Behcet's disease; ix/ no new biotherapies have shown high efficacy in systemic lupus erythematosus; x/ nanoparticles loaded with autoantigens induce Tregs and Bregs and may be a promising therapeutic option to treat auto-immune disease in the future; xi/ ipilimumab treatment (anti-CTLA4 antibody, immune checkpoint inhibitor) may induce complete remission in acute myeloid leukemia patients relapsing after haematological stem cell transplantation. Year 2016 is full of great discoveries in internal medicine keeping the dermatologist brain fully open minded.
[Mh] Termos MeSH primário: Medicina Interna
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/uso terapêutico
Anti-Hipertensivos/uso terapêutico
Antineoplásicos Imunológicos/uso terapêutico
Artrite Reumatoide/tratamento farmacológico
Asma/tratamento farmacológico
Doenças Autoimunes/tratamento farmacológico
Síndrome de Behçet/genética
Doenças Cardiovasculares/prevenção & controle
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Doenças Inflamatórias Intestinais/genética
Ipilimumab/uso terapêutico
Dermatopatias/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antihypertensive Agents); 0 (Antineoplastic Agents, Immunological); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Ipilimumab); 0 (SAR231893)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180213
[St] Status:MEDLINE


  6 / 8113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29224587
[Au] Autor:Madanat WY; Alawneh KM; Smadi MM; Saadeh SS; Omari MM; Bani Hani AB; Yazici H
[Ad] Endereço:Medical Department, Jordan's Friends of Behçet's Disease Patients Society, Amman, Jordan. wmadanat@orange.jo.
[Ti] Título:The prevalence of Behçet's disease in the north of Jordan: a hospital-based epidemiological survey.
[So] Source:Clin Exp Rheumatol;35 Suppl 108(6):51-54, 2017 Nov-Dec.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To estimate the prevalence of Behçet's disease (BD) in Jordan, with the additional aim of comparing this prevalence among hospital workers in other geographical areas. METHODS: In the first stage of our survey, 2,569 employees from 6 hospitals in north Jordan were interviewed using a screening questionnaire to identify individuals with recurrent oral ulcers (ROU), a previous diagnosis of BD (PDBD) and/or any major symptom related to BD. In the second stage, all individuals with ROU or PDBD identified at stage 1, were examined by 2 rheumatologists for the presence/confirmation of BD according to the International Study Group (ISG) criteria. Pathergy test was performed according to recommendations. RESULTS: ROU were present in 210 (8.2%) individuals. BD was confirmed in 10 employees with PDBD. Seven more BD patients were found. Mean age of 17 BD patients was 38.6±10.7 (range 26-65 y). M: F was 2.4:1. Pathergy test was positive in 8/17. A family history of ROU or BD was noted in 9 (52%) and 3 (25.0%), respectively, compared to 227 (8.9%) and 62 (2.6%) in the whole group, excluding the BD patients (p<0.001 and 0.008, respectively). The prevalence rate of BD in the north of Jordan was estimated as 66:10.000 (95% CI 34.8 to 97.5:10000). CONCLUSIONS: The results of this first ever survey indicated that the prevalence of BD in the north of Jordan is among the highest in the world. This prevalence can now be compared to hospital workers in other geographical areas.
[Mh] Termos MeSH primário: Síndrome de Behçet/epidemiologia
Hospitais
Úlceras Orais/epidemiologia
Recursos Humanos em Hospital
[Mh] Termos MeSH secundário: Adulto
Idoso
Síndrome de Behçet/diagnóstico
Síndrome de Behçet/genética
Feminino
Predisposição Genética para Doença
Inquéritos Epidemiológicos
Hereditariedade
Seres Humanos
Jordânia/epidemiologia
Masculino
Meia-Idade
Úlceras Orais/diagnóstico
Úlceras Orais/genética
Linhagem
Prevalência
Recidiva
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE


  7 / 8113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467587
[Au] Autor:Yasar B; Kiliçoglu G
[Ad] Endereço:Istanbul Training and Research Center, Baskent University, Istanbul, Turkey drbyasar@yahoo.com.
[Ti] Título:Behçet's disease-related superior vena cava syndrome and bleeding downhill varices: A rare complication.
[So] Source:Ulus Travma Acil Cerrahi Derg;23(2):170-172, 2017 Mar.
[Is] ISSN:1306-696X
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:Obstruction of the superior vena cava (SVC) due to any cause results in development of venous collaterals in the upper part of the esophagus, known as "downhill" varices. Although rare, bleeding can be life-threatening. Presently described is case of Behçet's diseaserelated SVC occlusion in a patient who presented with gastrointestinal bleeding from upper esophageal varices.
[Mh] Termos MeSH primário: Síndrome de Behçet
Hemorragia Gastrointestinal
Síndrome da Veia Cava Superior
[Mh] Termos MeSH secundário: Adulto
Hematemese
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.5505/tjtes.2016.92145


  8 / 8113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29287101
[Au] Autor:Jung YS; Han M; Kim DY; Cheon JH; Park S
[Ad] Endereço:Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
[Ti] Título:Cancer risk in Korean patients with Behçet's disease: A nationwide population-based study.
[So] Source:PLoS One;12(12):e0190182, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Various immune-mediated diseases are associated with increased malignancy risks. However, the relationship between Behçet's disease (BD) and cancer remains unclear. We conducted a nationwide, population-based study to determine the risk of cancer in patients with BD. METHODS: Using National Health Insurance claims records, we collected data from 2402 patients diagnosed with BD between 2013 and 2014. Standardized incidence ratios (SIRs) of overall and site-specific cancers in patients with BD in comparison with the general population were calculated. RESULTS: The risks of overall cancer (SIR, 3.54; 95% confidence interval, 2.35-5.11 in men and 2.17; 1.58-2.92 in women) and solid cancer (3.10; 1.94-4.69 in men and 2.13; 1.52-2.90 in women) were greater in patients with BD than in the general population. There were significantly increased risks for these solid cancers: colorectal (4.26; 1.38-9.94), liver (4.00; 1.09-10.25), bone/articular cartilage (55.66; 1.41-310.14), prostate (7.05; 1.45-20.60), and brain/central nervous system (28.32; 3.43-102.31) in men; and the lips/oral cavity/pharynx (13.97, 1.69-50.47), liver (12.78; 5.14-26.33), lungs (4.35; 1.18-11.13), other female genital organs (53.57; 1.36-298.49), and eyes (128.26; 3.24-714.59) in women. Patients with BD had a greater risk of myelodysplastic syndrome (MDS) than the general population did (65.72; 7.96-237.41 in men and 53.86; 11.11-157.40 in women), but not of hematological cancer. CONCLUSIONS: Compared to the general population, Korean patients with BD had greater risks of overall cancer, some solid cancers, and MDS, but not of hematological cancer.
[Mh] Termos MeSH primário: Síndrome de Behçet/complicações
Neoplasias/epidemiologia
Vigilância da População
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seres Humanos
Incidência
Masculino
Meia-Idade
Neoplasias/classificação
Neoplasias/complicações
República da Coreia/epidemiologia
Fatores de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190182


  9 / 8113 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27777341
[Au] Autor:Hu CJ; Pan JB; Song G; Wen XT; Wu ZY; Chen S; Mo WX; Zhang FC; Qian J; Zhu H; Li YZ
[Ad] Endereço:From the ‡Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China100730.
[Ti] Título:Identification of Novel Biomarkers for Behcet Disease Diagnosis Using Human Proteome Microarray Approach.
[So] Source:Mol Cell Proteomics;16(2):147-156, 2017 Feb.
[Is] ISSN:1535-9484
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Behcet disease (BD) is a chronic systemic vasculitis and considered as an autoimmune disease. Although rare, BD can be fatal due to ruptured vascular aneurysms or severe neurological complications. To date, no known biomarker has been reported for this disease, making it difficult to diagnosis in the clinics. To undertake this challenge, we employed the HuProt arrays, each comprised of ∼20,000 unique human proteins, to identify BD-specific autoantibodies using a Two-Phase strategy established previously. In Phase I, we profiled the autoimmunity on the HuProt arrays with 75 serum samples collected from 40 BD patients, 15 diagnosed autoimmune patients who suffer from Takayasu arteritis (TA; n = 5)), ANCA associated vasculitis (AAV; n = 5), and Sjogren's syndrome (SS; n = 5), and 20 healthy subjects, and identified 20 candidate autoantigens that were significantly associated with BD. To validate these candidates, in Phase II we constructed a focused array with these 20 candidate BD-associated antigens, and use it to profile a much larger cohort, comprised of serum samples collected from 130 BD patients, 103 autoimmune patients (i.e. 40TA, 40 AAV and 23 SS), and 110 healthy controls. This allowed us to validate CTDP1 (RNA polymerase II subunit A C-terminal domain phosphatase)as a BD-specific autoantigen. The association of anti-CTDP1 with BD patients was further validated using the traditional Western blotting analysis. In conclusion, anti-CTDP1 antibody serves a novel autoantibody for Behcet disease and is expected to help more accurate clinical diagnosis.
[Mh] Termos MeSH primário: Síndrome de Behçet/diagnóstico
Fosfoproteínas Fosfatases/metabolismo
Análise Serial de Proteínas/métodos
Proteômica/métodos
[Mh] Termos MeSH secundário: Adulto
Autoanticorpos/imunologia
Autoantígenos/metabolismo
Síndrome de Behçet/imunologia
Biomarcadores/metabolismo
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Autoantigens); 0 (Biomarkers); EC 3.1.3.16 (Phosphoprotein Phosphatases); EC 3.1.3.16 (carboxy-terminal domain phosphatase)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1074/mcp.M116.061002


  10 / 8113 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245353
[Au] Autor:Wang M; Sun W; Chen Z; Wang X; Lv J; Tan Q; Wang Y; Zhou J
[Ad] Endereço:aDepartment of Nephrology and Rheumatology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, ChinabSingapore Thong Chai Medical Institution, Singapore.
[Ti] Título:Multiple aneurysms and gastrointestinal involvement in Behcet's disease: A case report.
[So] Source:Medicine (Baltimore);96(49):e9131, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Behcet's disease (BD) is a rare systemic vasculitis disorder that can involve vessels of any size. PATIENT CONCERNS: A 60-year-old female had recurrent painful mouth ulcers about 30 years ago and recently presented with abdominal distension, conjunctival congestion, and chest pain in sequence. DIAGNOSES: The patient was diagnosed with BD according to the International Criteria for Behcet's Disease (ICBD). INTERVENTIONS: A therapy of glucocorticoids and cyclophosphamide was administered. OUTCOMES: After a 3-month treatment, follow-up examination showed a depression of the inflammation and a slight decrease of the arterial aneurysms. LESSONS: BD patients may get a delayed diagnosis because of the long duration between the first and subsequent manifestations. Suspect patients should be followed-up and the diagnosis of BD should be considered when multiple tissues or organs are involved.
[Mh] Termos MeSH primário: Aneurisma/etiologia
Síndrome de Behçet/complicações
Síndrome de Behçet/diagnóstico
Úlceras Orais/etiologia
[Mh] Termos MeSH secundário: Aneurisma/fisiopatologia
Síndrome de Behçet/tratamento farmacológico
Síndrome de Behçet/fisiopatologia
Feminino
Seres Humanos
Imunossupressores/uso terapêutico
Meia-Idade
Úlceras Orais/fisiopatologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009131



página 1 de 812 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde